Free Trial
NASDAQ:SPRB

Spruce Biosciences Q4 2024 Earnings Report

Spruce Biosciences logo
$0.07 +0.00 (+0.43%)
As of 05/30/2025 03:54 PM Eastern

Spruce Biosciences EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.37
One Year Ago EPS
N/A

Spruce Biosciences Revenue Results

Actual Revenue
$0.55 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$50.00 thousand
YoY Revenue Growth
N/A

Spruce Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, April 14, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Spruce Biosciences' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Spruce Biosciences Earnings Headlines

Spruce Biosciences Inc Ordinary Shares
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital
See More Spruce Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email.

About Spruce Biosciences

Spruce Biosciences (NASDAQ:SPRB), a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

View Spruce Biosciences Profile

More Earnings Resources from MarketBeat